According to Fierce Pharma, AstraZeneca is having trouble unloading its anti-infectives division. Part of the problem seems to be that they’re trying to spin out the whole package at once:
The pharma giant also specifically sought out venture groups that had been investing in anti-infectives in an effort to find a buyer for the Waltham, MA-based group. “The assets had little (if any) differentiation and were late to the market and the economics didn’t make sense,” the executive added.
Another player in the field says he took an early look at AstraZeneca’s proposition. “The challenge was that they wanted to spin out the whole pipeline plus a 20-person team,” he said. “The pipeline had a couple of interesting assets but they wanted to get paid for the uninteresting assets as well.”
The article says that people believe that AZ is getting close to making some sort of decision, since the whole process has been going on for longer than they wanted. I wonder how many of that 20-person team still remains?